← All trials
NCT05801978
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2023
- Primary completion
- Sep 30, 2025
- Completion date
- Sep 30, 2025
- First posted
- Apr 6, 2023
- Last posted
- Apr 24, 2023
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- Defense Advanced Research Projects AgencyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.